As of 2025-07-02, the Intrinsic Value of Kalvista Pharmaceuticals Inc (KALV) is -15.73 USD. This KALV valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.59 USD, the upside of Kalvista Pharmaceuticals Inc is -235.69%.
Based on its market price of 11.59 USD and our intrinsic valuation, Kalvista Pharmaceuticals Inc (KALV) is overvalued by 235.69%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.73 - -15.73 | -15.73 | -235.69% |
| P/E | (41.83) - (82.72) | (62.99) | -643.5% |
| DDM - Stable | (22.88) - (79.73) | (51.31) | -542.7% |
| DDM - Multi | (7.03) - (19.42) | (10.36) | -189.4% |
| Market Cap (mil) | 576.25 |
| Beta | 1.03 |
| Outstanding shares (mil) | 49.72 |
| Enterprise Value (mil) | 423.97 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.59% |
| Cost of Debt | 5.00% |
| WACC | 7.13% |